Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas
Crossref DOI link: https://doi.org/10.1007/s12032-014-0353-5
Published Online: 2014-12-16
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yun, Hou
Zhang, Hui lai
Wang, Hua-qing
Text and Data Mining valid from 2014-12-16